MARC details
000 -LEADER |
fixed length control field |
11042nam a22005053i 4500 |
001 - CONTROL NUMBER |
control field |
EBC6784040 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
MiAaPQ |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20220524155546.0 |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
fixed length control field |
m o d | |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr cnu|||||||| |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
220504s2021 xx o ||||0 eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9780128198841 |
Qualifying information |
(electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
Canceled/invalid ISBN |
9780128198698 |
035 ## - SYSTEM CONTROL NUMBER |
System control number |
(MiAaPQ)EBC6784040 |
035 ## - SYSTEM CONTROL NUMBER |
System control number |
(Au-PeEL)EBL6784040 |
035 ## - SYSTEM CONTROL NUMBER |
System control number |
(OCoLC)1285170781 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
MiAaPQ |
Language of cataloging |
eng |
Description conventions |
rda |
-- |
pn |
Transcribing agency |
MiAaPQ |
Modifying agency |
MiAaPQ |
082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
615.1 |
100 1# - MAIN ENTRY--PERSONAL NAME |
Personal name |
Huang, Shiew-Mei. |
245 10 - TITLE STATEMENT |
Title |
Atkinson's Principles of Clinical Pharmacology. |
250 ## - EDITION STATEMENT |
Edition statement |
4th ed. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
San Diego : |
Name of producer, publisher, distributor, manufacturer |
Elsevier Science & Technology, |
Date of production, publication, distribution, manufacture, or copyright notice |
2021. |
264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Date of production, publication, distribution, manufacture, or copyright notice |
�2022. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
1 online resource (764 pages) |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Intro -- Atkinson's Principles of Clinical Pharmacology -- Copyright -- Contents -- Contributors -- Preface to the first edition -- Preface to the fourth edition -- Chapter 1: Introduction to clinical pharmacology -- Background -- Optimizing use of existing medicines -- Evaluation and development of medicines -- Pharmacokinetics -- The concept of clearance -- Clinical estimation of renal function -- Dose-related toxicity often occurs when impaired renal function is unrecognized -- References -- Additional sources of information -- Chapter 2: Clinical pharmacokinetics -- The target concentration strategy -- Monitoring serum concentrations of digoxin as an example -- General indications for drug concentration monitoring -- Concepts underlying clinical pharmacokinetics -- Initiation of drug therapy (concept of apparent distribution volume) -- Continuation of drug therapy (concepts of elimination half-life and clearance) -- Elimination half-life -- Elimination clearance -- Drugs not eliminated by first-order kinetics -- Mathematical basis of clinical pharmacokinetics -- First-order elimination kinetics -- Concept of elimination half-life -- Relationship of k to elimination clearance -- Cumulation factor -- The plateau principle -- Application of Laplace transforms to pharmacokinetics -- References -- Study problems -- Chapter 3: Compartmental analysis of drug distribution -- Fit-for-purpose modeling of drug distribution -- Physiological significance of drug distribution volumes -- Physiological basis of multicompartmental models of drug distribution -- Formulation of multicompartmental models -- Basis of multicompartmental structure -- Mechanisms of transcapillary exchange -- Clinical consequences of different drug distribution patterns -- Drugs with faster elimination than distribution -- Estimating model parameters from experimental data. |
505 8# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Derivation of equations for a two-compartment model -- Calculation of rate constants and compartment volumes from data -- Different estimates of apparent volume of distribution -- References -- Study problems -- Chapter 4: Drug absorption and bioavailability -- Drug absorption -- Metabolism by intestinal bacteria -- Presystemic elimination -- Drug-drug and food-drug interactions -- Bioavailability -- Absolute bioavailability -- Relative bioavailability -- In vitro prediction of bioavailability -- Kinetics of drug absorption after oral administration -- Time to peak level -- Value of peak level -- Use of convolution/deconvolution to assess in vitro-in vivo correlations -- References -- Study problems -- Chapter 5: Effect of kidney disease on pharmacokinetics -- Drug dosing in patients with impaired kidney function -- Effects of kidney disease on renal drug elimination mechanisms -- Excretion mechanisms: Filtration and secretion -- Reabsorption mechanisms -- Renal metabolism -- Analysis and interpretation of renal excretion data -- Effects of impaired kidney function on nonrenal clearance pathways -- Nonrenal metabolism -- Nonrenal transport -- Potential mechanisms of altered nonrenal clearance -- Effects of kidney disease on drug distribution -- Plasma protein binding of acidic drugs -- Plasma protein binding of basic and neutral drugs -- Tissue binding of drugs -- Effects of kidney disease on drug absorption -- Study problem -- References -- Chapter 6: Pharmacokinetics in patients requiring renal replacement therapy -- Kinetics of intermittent hemodialysis -- Solute transfer across dialyzing membranes -- Calculation of dialysis clearance -- Patient factors affecting hemodialysis of drugs -- Hemodynamic changes during Dialysis -- Kinetics of CRRT and sustained renal replacement therapy -- Clearance by continuous hemofiltration. |
505 8# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Clearance by continuous hemodialysis and SLED -- Extracorporeal clearance during continuous renal replacement therapy -- Clinical considerations -- Drug dosing guidelines for patients requiring renal replacement therapy -- Extracorporeal therapy of patients with drug toxicity -- References -- Chapter 7: Effect of liver disease on pharmacokinetics -- Physiologic determinants of hepatic drug clearance -- Hepatic elimination of drugs -- Restrictively metabolized drugs (ER0.3) -- Effect of changes in protein binding on hepatic clearance -- Effect of changes in intrinsic clearance on hepatic drug clearance -- Drugs with an intermediate extraction ratio (0.3ER0.7) -- Nonrestrictively metabolized drugs (ER0.70) -- Biliary excretion of drugs -- Enterohepatic circulation -- Effects of liver disease on pharmacokinetics -- Acute hepatitis -- Chronic liver disease and cirrhosis -- Pharmacokinetic consequences of liver cirrhosis -- Influence of portosystemic shunting on nonrestrictively metabolized drugs -- Consequences of decreased protein binding -- Consequences of hepatocellular changes -- Use of therapeutic drugs in patients with liver disease -- Classification schemes for liver function -- FDA guidance for industry on pharmacokinetic studies in patients with impaired hepatic function -- Other tools for the assessment of liver function -- Effects of liver disease on the hepatic elimination of drugs -- Correlation of laboratory tests with drug metabolic clearance -- Use of probe drugs to characterize hepatic drug clearance -- Effects of liver disease on the renal elimination of drugs -- Effects of liver disease on patient response -- Modification of drug therapy in patients with liver disease -- References -- Chapter 8: Noncompartmental and compartmental approaches to pharmacokinetic data analysis -- Introduction. |
505 8# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Kinetics, pharmacokinetics, and pharmacokinetic parameters -- Kinetics and the link to mathematics -- The pharmacokinetic parameters -- Accessible pool parameters -- System parameters -- Moments -- Noncompartmental analysis -- Noncompartmental model -- Kinetic parameters of the noncompartmental model -- The single accessible pool model -- The two accessible pool model -- Estimating the kinetic parameters of the noncompartmental model -- Estimating AUC and AUMC using sums of exponentials -- Estimating AUC and AUMC using other functions -- Estimating t1tnC(t)dt and t1tntC(t)dt -- Extrapolating from tn to infinity -- Estimating AUC and AUMC from 0 to infinity -- Compartmental analysis -- Definitions and assumptions -- Linear, constant coefficient compartmental models -- Parameters estimated from compartmental models -- Experimenting on compartmental models: Input and measurements -- Nonlinearities in compartmental models -- Calculating pharmacokinetic parameters from a compartmental model -- Model parameters -- Residence time calculations -- Noncompartmental versus compartmental models -- Models of data vs. models of system -- The equivalent sink and source constraints -- Linearity and time invariance -- Recovering pharmacokinetic parameters from compartmental models -- Conclusion -- References -- Chapter 9: Population pharmacokinetics -- Introduction -- Analysis of pharmacokinetic data -- Structure of pharmacokinetic models -- Fitting individual data -- Population pharmacokinetics -- Population analysis methods -- The na�ive pooled data method -- The two-stage method -- Nonlinear mixed effects modeling method -- Model comparison -- Model evaluation -- Model applications -- Mirogabalin case study -- Milademetan case study -- Conclusions -- References -- Chapter 10: Pathways of drug metabolism -- Introduction. |
505 8# - FORMATTED CONTENTS NOTE |
Formatted contents note |
The chemistry and enzymology of drug metabolism -- Oxidations and nonconjugation reactions -- Cytochrome P450 monooxygenases -- Cytochrome P450 families -- The CYP3A family -- The CYP2C family -- The CYP2D6 family -- The CYP 1A family -- Non-CYP oxidations -- Flavin-containing monooxygenases -- Monoamine oxidases -- Molybdenum-containing oxidases -- Esterases -- Epoxide hydrolases -- Conjugation reactions -- Glucuronosyl transferases -- Sulfotransferases -- Acetyl transferases -- Methyltransferases -- Glutathione transferases -- References -- Chapter 11: Bioanalytical methods: Technological platforms and method validation -- Technological platforms of bioassays -- High performance/pressure liquid chromatography -- Chromatographic column -- Mobile phase -- Detectors -- Alternative chromatographic approaches -- Gas chromatography -- LC-MS/MS and high resolution mass spectrometry (HRMS) -- Internal standards -- Accelerator mass spectrometry -- Immunoassays -- Polymerase chain reaction assays -- Method validation -- Sample analysis -- Cross-validation -- Case examples -- Interference -- Establishing assay range -- Impact of sample handling or instability -- Assessing results from two assays: Cross-validation -- Conclusion -- References -- Chapter 12: Clinical pharmacogenetics -- Introduction -- General principles -- Pharmacogenetics and pharmacogenomics -- Human genetics -- Indications for performing pharmacogenetic studies -- Genetic analysis techniques and informatics -- Examples of clinically relevant genetic polymorphisms -- Genetic variation in Phase I metabolic pharmacogenes -- CYP2B6 -- CYP2C9 -- CYP2C19 -- CYP2D6 -- CYP3A4 and CYP3A5 -- Genetic variation in Phase II metabolic pharmacogenes -- Thiopurine S-methyltransferase (TPMT) -- N-Acetyltransferase 2 (NAT2) -- Target/efficacy pharmacogenetics. |
505 8# - FORMATTED CONTENTS NOTE |
Formatted contents note |
Vitamin K epoxide reductase complex, subunit 1 (VKORC1). |
588 ## - SOURCE OF DESCRIPTION NOTE |
Source of description note |
Description based on publisher supplied metadata and other sources. |
590 ## - LOCAL NOTE (RLIN) |
Local note |
Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2022. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
655 #4 - INDEX TERM--GENRE/FORM |
Genre/form data or focus term |
Electronic books. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Lertora, Juan J. L. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Vicini, Paolo. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Atkinson, Jr., Arthur J. |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
Relationship information |
Print version: |
Main entry heading |
Huang, Shiew-Mei |
Title |
Atkinson's Principles of Clinical Pharmacology |
Place, publisher, and date of publication |
San Diego : Elsevier Science & Technology,c2021 |
International Standard Book Number |
9780128198698 |
797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) |
Corporate name or jurisdiction name as entry element |
ProQuest (Firm) |
850 ## - HOLDING INSTITUTION |
Holding institution |
|
856 40 - ELECTRONIC LOCATION AND ACCESS |
Uniform Resource Identifier |
<a href="https://ebookcentral.proquest.com/lib/vajira-ebooks/detail.action?docID=6784040">https://ebookcentral.proquest.com/lib/vajira-ebooks/detail.action?docID=6784040</a> |
Public note |
Click to View |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Source of classification or shelving scheme |
National Library of Medicine Classification |
Koha item type |
Electronic Book |